NCT02376400View on ClinicalTrials.gov

A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

September 30, 2016

Conditions
Healthy
Interventions
BIOLOGICAL

MVA-BN-Filo

One 0.5 milliliter (ml) intramuscular (IM) injection of 1\*10\^8, (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1, 29 or 57.

BIOLOGICAL

Ad26.ZEBOV

One 0.5 mL IM injection of 5\*10\^10 viral particles (vp) on Day 1, 29 or 57.

BIOLOGICAL

Placebo

One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.

Trial Locations (2)

Unknown

Mwanza

Entebbe

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT02376400 - A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants | Biotech Hunter | Biotech Hunter